Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of ...

Key players in the Hematologic Malignancies Therapeutics Market include Pfizer, Inc., F. Hoffmann-La Roche Ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline ...

Request To Download Free Sample of This Strategic Report @- The Global Remote Patient Monitoring Devices Market is on the brink of transformative growth, poised to exceed USD 1,882.75 Million by 2025 ...

The growing prevalence of cardiovascular and thrombotic disorders is driving strong demand for D-dimer testing. As blood clot-related risk factors continue to increase, the need for precise ...

LPL Financial’s latest acquisition from Osaic is a California-based $410 million firm that specializes in working with ...

The global cancer tissue diagnostic market is on track for significant growth, with a projected increase from USD 15,302.2 ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

The global drug-induced immune hemolytic anemia market, valued at approximately USD 7.8 billion in 2023, is poised for ...

Conjunctival breach and a late onset are common in cases of endophthalmitis associated with implantation of an anti-VEGF delivery device.

The Minimal Residual Disease Testing Market is projected to reach $4.45 billion by 2031, at a CAGR of 14.6% during the forecast period 2024–2031. The growth of the minimal residual disease testing ...

Roche's bid to block a generic SMA drug risks public health by limiting affordable access, say patient groups, highlighting high costs and patent issues.

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...